Deaths from Alzheimer's disease rose 142% between 2000 and 2022.1
When the trial criteria for the amyloid antibodies were applied to real patients with mild cognitive impairment, 47% met the inclusion criteria and 8% survived the exclusions.2
Most people with early Alzheimer's cannot take the drugs already approved. The next mechanism has to be one they can.